28 February 2018
Napanee, Ontario – NovaVive Inc., an animal health immunobiology company, today announced that its USDA- and CFIA-approved immunotherapy for calf scours, Amplimune®, has received an Organic Materials Review Institute (OMRI) Listing in the U.S.A. This means that OMRI is allowing Amplimune to be used in compliance with the USDA National Organic Program.
Amplimune is a potent immunomodulator that reduces the clinical signs and mortality associated with E. coli K99 diarrhea in neonatal calves. The product is an emulsion of mycobacterium cell wall fractions (MCWF) that, when injected into the animal, enhances innate immunity to fight bacterial infections without the use of antibiotics. The product has received regulatory approval for sale in both the U.S.A. and Canada.
Studies have shown that a single, 1 mL dose of Amplimune can induce an immediate innate immune response in the neonatal calf. In a pivotal challenge study, 90% of colostrum-deprived calves developing E. coli K99 diarrhea survived when treated with 1 mL of Amplimune vs. 30% of control calves. Those in the treatment group received a single dose at the first signs of clinical disease.
“Antibiotics are not an option for treating bacterial diseases in organic cattle,” said Graeme McRae, President of NovaVive Inc. “We are pleased to offer a safe and effective alternative to organic cattle producers, and we look forward to working with both producers and veterinarians to assess additional dairy and beef cattle diseases where antibiotic alternatives are needed.”
About the Organic Materials Review Institute (OMRI)
OMRI supports organic integrity by developing clear information and guidance about materials, so that producers know which products are appropriate for organic operations. OMRI is a nonprofit organization that provides an independent review of products, such as fertilizers, pest controls, livestock health care products, and numerous other inputs that are intended for use in certified organic production and processing. When companies apply, OMRI reviews their products against the organic standards. Acceptable products are OMRI Listed® and appear on the OMRI Products List© or OMRI Canada Products List©. OMRI also provides technical support and training for professionals in the organic industry.
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the U.S. Certain formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease. Other formulations have been developed as anticancer therapies in dogs and horses. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about the Company, please visit www.NovaVive.ca, or contact:
Graeme McRae, President or Jennifer Shea, V-P, Investor Relations & Business
Phone: 613-391-3837 Jennifer.Shea@NovaVive.ca